Overview

CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma in Need of Definitive Local Control of Cancer

Status:
Not yet recruiting

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

This is a single-center, open-label, phase I study designed to determine the maximum tolerated dose (MTD) and safety profile of CPI-613® when used concomitantly with chemoradiation for local control of pancreatic adenocarcinoma (PDAC).

Phase:

Phase 1

Details

Lead Sponsor:

Medical College of Wisconsin

Collaborator:

Rafael Pharmaceuticals Inc.

Treatments:

Gemcitabine
Thioctic Acid